VIVUS (VVUS) Said Qnexa Shows Improved Glucose Control in Obese Non-Diabetic Subjects
Tweet Send to a Friend
VIVUS, Inc. (NASDAQ: VVUS) announced additional results from the EQUATE study (OB-301), a phase 3 obesity trial with Qnexa, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
